Eiger BioPharmaceuticals to focus Avexitide for hyperinsulinemic hypoglycaemia indicationsEiger BioPharmaceuticals has revealed it will focus its development efforts on advancing avexitide in hyperinsulinemic hypoglycaemia...
Use of avexitide in patients with post-bariatric hypoglycaemia and hyperinsulinemic hypoglycaemiaPhase 2b results of avexitide (Eiger BioPharmaceuticals) in patients with post-bariatric hypoglycemia (PBH) and hyperinsulinemic...
Standardisation of OAGB is key to reducing surgical errors and ensuring consistent patient outcomes1 day ago